• Phare
  • Validé par KD/KO

Anticorps Polyclonal de lapin anti-TRAIL/CD253

TRAIL/CD253 Polyclonal Antibody for WB, IHC, IF/ICC, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

WB, IHC, IF/ICC, ELISA

Conjugaison

Non conjugué

N° de cat : 27064-1-PBS

Synonymes

TNFSF10, TRAIL, Apo-2 ligand, CD253, Protein TRAIL



Informations sur le produit

27064-1-PBS cible TRAIL/CD253 dans les applications de WB, IHC, IF/ICC, ELISA et montre une réactivité avec des échantillons Humain

Réactivité Humain
Hôte / Isotype Lapin / IgG
Clonalité Polyclonal
Type Anticorps
Immunogène TRAIL/CD253 Protéine recombinante Ag25746
Nom complet tumor necrosis factor (ligand) superfamily, member 10
Masse moléculaire calculée 281 aa, 33 kDa
Poids moléculaire observé 33 kDa, 20 kDa
Numéro d’acquisition GenBankBC032722
Symbole du gène TRAIL
Identification du gène (NCBI) 8743
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par affinité contre l'antigène
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

TRAIL, also known as CD253 or TNFSF10 (tumor necrosis factor superfamily member 10), is a typical death ligand expressed on natural killer cells and cytotoxic T lymphocytes. This protein preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues. TRAIL induces apoptotic cell death in cancer by binding to its functional death receptors, death receptor (DR) 4 (TNFRSF10A/TRAIL-R1) and DR5 (TNFRSF10B/TRAIL-R2) to activate the extrinsic apoptosis pathway. TRAIL also activates c-Jun N-terminal kinase (MAPK8/JNK) and the transcription factor nuclear factor-κB (NFκB). The binding of this protein to its receptors has been shown to trigger the activation of MAPK8/JNK, caspase 8, and caspase 3.

{{ptg:RelatedPrimaryAntibodies}}